A recent clinical trial of a virotherapy approach, consisting of an engineered poliovirus, has
provided evidence of apparently durable responses in patients with recurrent glioblastoma.
The results of this trial and others indicate that virotherapy might be an effective tool in
anticancer immunotherapy. Yet, caution must be exercised until appropriately powered
randomized clinical trials truly show efficacy.